GET YOUR PATIENT STARTED IN JUST 3 EASY STEPS:

one.png

Download the SareptAssist START Form

 

2.png

With your patient, fill out the START Form and fax it to 1-800-621-5203.

3.png

A dedicated SareptAssist Case Manager will contact your patient to welcome them to the program and explain how they can help.


Ready to begin prescribing EXONDYS 51? Here’s what you need to know. 

EXONDYS 51 DOSING & ADMINISTRATION GUIDE
7-1-brochure-dosing-guide
EXONDYS 51 DOSING & ADMINISTRATION GUIDE

This guide provides recommended dosing guidelines, along with important safety information, storage instructions, and information on preparing and infusing EXONDYS 51. 

Download Guide

EXONDYS 51 BILLING & CODING GUIDE
7-1-brochure-billing
EXONDYS 51 BILLING & CODING GUIDE

Find important billing and coding information at a glance, plus supporting documents to submit when your patient’s health plan requires prior authorization.

Download Guide

Here’s what you need to enroll your patient in SareptAssist, plus additional resources designed to assist you in getting your patient started on EXONDYS 51. 

SAREPTASSIST START FORM
7-1a-start
SAREPTASSIST START FORM

With your patient’s consent and signature, complete this form to enroll them in SareptAssist, our patient support program. 
This form authorizes a Case Manager to start a benefits investigation to help with insurance benefits. Fax the completed form with the patient’s Genetic Mutation Worksheet to 1-800-621-5203.

Download Form (ENGLISH)
Download Form (SPANISH)
 

GENETIC MUTATION WORKSHEET
7-1a-worksheet
GENETIC MUTATION WORKSHEET

This worksheet will help you determine whether your patient is appropriate for EXONDYS 51 therapy. Fax the completed form with the patient’s START Form to 1-800-621-5203.

Download Worksheet

sareptassist.png

Headset    QUESTIONS? LET SAREPTASSIST HELP.
    Give us a call. 1-888-SAREPTA (1-888-727-3782)
    Case Managers are available Monday – Friday  8:30am – 6:30pm ET. 
    Download SareptAssist START Form

GET THE LATEST UPDATES FROM SAREPTA.

Sign up for news from Sarepta Therapeutics, including product updates, reimbursement information, and services that may be of interest to you and your patients.

INDICATION

EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Read More

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions, including rash and urticaria, pyrexia, flushing, cough, dyspnea, bronchospasm, and hypotension, have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.

Adverse reactions in DMD patients (N=8) treated with EXONDYS 51 30 or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended.

In the 88 patients who received ≥30 mg/kg/week of EXONDYS 51 for up to 208 weeks in clinical studies, the following events were reported in ≥10% of patients and occurred more frequently than on the same dose in Study 1: vomiting, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection.

Please see the full Prescribing Information for EXONDYS 51 (eteplirsen).